Clinical research is evolving rapidly, with decentralized clinical trials (DCTs) playing a leading role in shaping the future. By allowing patients to participate remotely, DCTs use digital tools and flexible designs to remove traditional barriers to participation. For sponsors, CROs, and research sites, these models offer opportunities to improve recruitment, increase retention, and capture more
Here at Innovative Trials, we’ve been in the business of accelerating patient access to life-changing treatments for 15 years. According to official figures from March 2025, only around 1 in 10 (11.6%) UK businesses reach this landmark anniversary, so we would like to take a moment to thank our amazing clients and everyone we
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and diversity,
Clinical trials are essential to the development of safe and effective treatments, yet many potential participants feel uncertain about joining. Understanding and addressing the barriers to clinical trial participation is vital for building trust and ensuring that research reflects the needs of all patients. Common barriers to clinical trial participation Fear and uncertainty For many
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and diversity,
Clinical trial patient recruitment and retention practices have significantly advanced over the last 15 years thanks to technological innovations and the rise of AI, shifting patient expectations and the increased, and much-needed, spotlight on diversity and inclusion. At the same time however, clinical trial patient recruitment remains as challenging as ever. At Innovative Trials,
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and diversity,
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and diversity,
Artificial intelligence (AI) in clinical research has the potential to accelerate patient access to new treatments by streamlining the drug development process and helping to generate more robust data, which will inevitably aid regulatory decision-making. But alongside AI’s potential promise comes several challenges that the pharmaceutical industry will need to consider – and
Several factors affect clinical trial success, such as patient recruitment and retention, protocol design and compliance, study duration, and high-quality partnerships between sponsors and non-industry collaborators1. But success can also rely on other circumstances like political decisions, technological advances and financial uncertainties. So far this year, we have witnessed several announcements that could